New drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2016-06-01
|
| Серія: | Prostate International |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2287888216300216 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|